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Abstract
Amenamevir (formerly ASP2151) induces cytochrome P450 (CYP)2B6 and CYP3A4 and inhibits CYP2C8. We
conducted 2 studies, 1 using montelukast as a probe to assess CYP2C8 and the other bupropion to assess CYP2B6. The
montelukast study examined the effect of amenamevir on the pharmacokinetics of montelukast in 24 healthy men:
each subject received montelukast 10 mg alone, followed by montelukast 10 mg with amenamevir 400 mg, or vice
versa after a washout period. In the bupropion study, 24 subjects received a single dose of 150 mg bupropion on days
1, 15, 22, and 29, and repeated once-daily doses of 400 mg amenamevir on days 6-15. Amenamevir increased peak
concentration and area under the concentration-time curve of montelukast by about 22% (ratio 121.7%, 90%CI [114.8,
129.1]; 121% [116.2, 128.4], respectively) with a similar increase in hydroxymontelukast (ratio 121.4%, 90%CI [106.4,
138.5]; 125.6 % [111.3, 141.7]). Amenamevir reduced peak concentration and area under the concentration-time
curve of bupropion by 16% (84.29%, 90%CI [78.00, 91.10]; 84.07%, 90%CI [78.85, 89.63]), with recovery after 1 week;
the pharmacokinetics of the primary metabolite hydroxybupropion was unaffected. Thus, amenamevir increased
plasma concentrations of montelukast and decreased those of bupropion, but it did not do so enough to require dose
adjustment of coadministered substrates of either CYP2C8 or CYP2B6.
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Amenamevir is an orally available non–nucleoside
analogue inhibitor of the helicase-primase enzyme
complex essential for herpesvirus DNA replication. It
has activity against herpes simplex types 1 and 2 and
varicella zoster virus and has shown promise in early
clinical trials.1 Herpes simplex infection is extremely
common and can lead to serious complications such
as encephalitis and hepatitis, especially in immuno-
compromised patients. All other currently licensed
medicines for herpesvirus infections act by inhibiting
DNA polymerase and are first activated by viral
enzymes so that they are active only in virus-infected
cells.2 The treatment of choice since the late 1970s has
been acyclovir, which is activated by viral thymidine
kinase, which some strains lack, leading to resistance in
about 1% in the general population and 3.5% to 14% in
immunocompromised patients.3 Alternative treatment
options are therefore required.
The pharmacokinetics and metabolism of ame-
namevir have previously been investigated in preclinical
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and clinical studies undertaken by Maruho (unpub-
lished data held by the company). In healthy volunteers
amenamevir was rapidly absorbed following single oral
doses with maximum plasma concentration (Cmax)
1.33-2.5 hours independent of dose. During repeated
dosing, Cmax and the area under the concentration-time
curve (AUC) decreased between the first dose (day 1),
an intermediate dose (day 9), and the last dose (day
16), suggesting autoinduction of metabolism, probably
via cytochrome P450 (CYP)3A4/5. AUC and Cmax
increased less than dose proportionally in dose-ranging
studies. Plasma protein binding of 14C-amenamevir in
humans was about 75%, and t½ about 7-8 hours. After
a single oral dose of 200 mg 14C-amenamevir, 74.6%
of 14C-radioactivity was recovered in feces. These data
are consistent with later pharmacokinetic analyses of
studies in healthy volunteers4 and patients.5
The metabolic profile of amenamevir was evaluated
in vitro using pooled liver microsomes and cryopre-
served hepatocytes of mouse, rat, rabbit, dog, and
human origin. The major human metabolite was a
monohydroxy derivative (AS1955888-00, Mo4, R5),
which was also detected in all other species tested.
CYP isoforms involved in amenamevir metabolism
were studied in vitro using human liver microsomes.
Amenamevir’s metabolism correlated significantly with
CYP2B6, CYP2C19, and CYP3A4/5 activity. The cor-
relation was strongest with CYP3A4/5 (0.9236 r2 co-
efficient of determination, P < .0001), suggesting a
major role for CYP3A4/5 in the metabolism of ame-
namevir, whereas correlation with CYP2B6 (0.3578 r2,
P= .0144) and CYP2C19 was less marked (0.3489 r2, P
= .0160). CorrelationwithCYP2C8wasweaker (0.1967
r2, P = .0853).
The potential for amenamevir to inhibit cytochrome
metabolism was evaluated in vitro using human
liver microsomes and CYP-selective substrates. Ame-
namevir had weak direct inhibitory activity against
CYP2C8 (IC50 69 μmol/L) but no activity against
CYP2B6 in the range of concentrations studied (0.1 to
100 μmol/L) (IC50 >100 μmol/L).
To investigate the potential of amenamevir to in-
duce CYP2B6, CYP2B6 activity and gene expression
were measured in human hepatocytes with or with-
out pretreatment for 72 hours with amenamevir. After
pretreatment with 2, 20, and 200 μmol/L amenamevir,
CYP2B6 activity increased 1.4-, 1.9-, and 2.9-fold, re-
spectively, and CYP2B6 gene expression increased by
1.9-, 4.5-, and 4.8-fold, respectively, compared with
the negative control. Those results suggest that ame-
namevir has the potential to induce CYP2B6.
We report here 2 studies in healthy volunteers
that were part of a series of investigations to eluci-
date potential interactions. Two probe substrates were
selected: montelukast to investigate effects of ame-
namevir on CYP2C8 and bupropion to test effects on
CYP2B6.
(1) Montelukast is an orally available leukotriene re-
ceptor antagonist used for the preventive treat-
ment of asthma and seasonal allergic rhinitis. It
is metabolized to its primary metabolite methyl-
hydroxymontelukast (M6) via 36-hydroxylation
by CYP2C8, which is also responsible for sub-
sequent conversion to the secondary metabolite
montelukast dicarboxylic acid (M4). CYP2C8 is
thought to account for 70% to 80% of mon-
telukast’s metabolism in vivo, with most of the re-
mainder accounted for by CYP3A4-mediated con-
version to M5a and M5b metabolites: less than
0.2% is eliminated in urine.6–11 This, together with
its benign safety profile, makes it an appropriate
choice as a CYP2C8 probe in healthy subjects.
(2) Bupropion is an orally available antidepressant
and nonnicotine smoking cessation aid that is
thought to exert its activity by reuptake inhibi-
tion of norepinephrine and dopamine and by
noncompetitive antagonism of nicotinic acetyl-
choline receptors.12,13 It is metabolized in vivo to
3 primary active metabolites: hydroxybupropion,
threohydrobupropion, and erythrohydrobupro-
pion. Hydroxybupropion has around 50% of
the activity of bupropion, but, as its Cmax is 4-7
times greater and AUC about 10-fold greater, it is
responsible for most of bupropion’s activity.14,15
Threohydrobupropion concentrations are about
5-fold greater than that of bupropion, and ery-
throhydrobupropion concentrations are similar
to those of bupropion, but they are only 20% as
potent as the parent.16 Hydroxybupropion forma-
tion is closely correlated with CYP2B6 activity in
human microsomes and with CYP2B6-specific N-
demethylation of S-mephenytoin and can be 95%
inhibited by a CYP2B6-specific monoclonal anti-
body. Bupropion’s other metabolites are formed
independently of cytochrome activity.17 Thus,
measurement of hydroxybupropion formation can
be used to investigate CYP 2B6 metabolism of
bupropion.
Subjects and Methods
Both studies were done concurrently at Hammersmith
Medicines Research (HMR), London, after approval
by both the Medicines and Healthcare products Regu-
latory Agency (MHRA) and the London-Brent Ethics
Committee. The studies were conducted in accordance
with the International Conference on Harmonisation
Good Clinical Practice Guidelines and the ethical
principles outlined in the Declaration of Helsinki.
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The montelukast study (EudraCT no 2014-003955-73)
lasted from December 2014 to April 2015, and the
bupropion study (EudraCT no 2014-004656-59) from
February to April 2015.
Subjects
Each study recruited the planned number of 24 healthy
male volunteers aged 18-45 years, deemed healthy on
the basis of medical history, medical examination,
vital signs, electrocardiogram, laboratory safety tests
on blood and urine, and urine tests for drugs of abuse
(Table 1). During the study, smoking, alcohol, caffeine,
all enzyme-inducing foodstuffs, and concomitant
medications were prohibited. Subjects fasted overnight
until a standardized light breakfast, which they fin-
ished 30 minutes before dosing. No food or drink was
then allowed until 4 hours after dosing. Subjects took
standard meals and drinks at 4, 10, and 24 hours after
dosing and then at standard meal times on nondosing
days. Safety tests on blood and urine, vital signs, and
medical examination were done at appropriate intervals
throughout each study.
Montelukast Study
This was a randomized, single-center, open-label, 2-way
crossover drug-drug interaction study to investigate the
effect of a single oral dose of amenamevir on the phar-
macokinetics of a single oral dose of montelukast in 24
healthy men.
Each subject received montelukast 10 mg alone, fol-
lowed 2 weeks later by montelukast 10 mg with ame-
namevir 400 mg, or vice versa; 400 mg amenamevir was
selected because it was the projected therapeutic dose
daily dose in Japan. Likewise, 10 mg montelukast was
selected on the basis that it is the adult daily dose for
treatment of asthma and seasonal allergies in adults
and is well tolerated in healthy volunteers.18
Subjects were resident on the ward from the after-
noon of the day before dosing (day –1) until day 4
and subsequently returned to give blood samples for
pharmacokinetic analysis at 7 and 14 days after their
dose of amenamevir. Plasma samples for analysis of
montelukast and methyl-hydroxymontelukast were ob-
tained predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8,
10, 12, 16, 20, 24, 30, 36, 48, and 72 hours after dos-
ing. Subjects returned for a final follow-up visit about
30 days after their last dose.
Bupropion Study
This was a single-center, open-label drug-drug inter-
action study to investigate the effect of amenamevir-
mediated CYP2B6 induction on the probe substrate
bupropion. Subjects received a single dose of 150 mg
bupropion on days 1, 15, 22, and 29 and once-daily
doses of 400 mg amenamevir on days 6-15 (Figure 1).
Subjects were resident on the ward on 3 occasions: from
the day before the first dose (day –1) until day 19; from
day 21 until day 26; and from day 28 until day 33. Sub-
jects returned for an outpatient visit on day 36 and a
final follow-up visit on day 45. Blood samples for assay
of bupropion and hydroxybupropion were taken before
each dose of bupropion and at 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9,
10, 12, 24, 36, 48, 60, 72, and 96 hours afterward (Sup-
plementary Table S1).
Blood samples for assay of amenamevir were taken
at predose on days 6-14, and before and frequently up
to 24 hours after dosing with amenamevir on day 15.
Safety and Tolerability Assessments
Safety and tolerability assessments included adverse
events, vital signs, 12-lead electrocardiogram, physical
examination, and clinical laboratory tests.
Assays
Plasma concentrations of all compounds and metabo-
lites were determined using validated liquid chro-
matography tandem mass spectrometry by Shin
Nippon Biomedical Laboratories, Ltd (Tokyo, Japan)
and Analytical Services International (London,
UK). The lower limit of quantification (LLQ) was
5 ng/mL for amenamevir, 10 ng/mL for montelukast, 1
ng/mL for methyl-hydroxymontelukast, 2.5 ng/mL for
bupropion, and 10 ng/mL for hydroxybupropion.
Blood samples for bupropion, hydroxybupropion,
montelukast, and methyl-hydroxymontelukast were
collected in lithium heparin tubes. Plasma was sepa-
rated by centrifugation at1500g for 10minutes at 4°C,
then stored at –20°C or below until analysis by Analyt-
ical Services International as described below.
Blood samples for amenamevir and AS1955888-00
were collected in sodium heparin tubes and prepared
as above before assay by Shin Nippon Biomedical
Laboratories, as described by Adeloye et al.19
Bupropion
Preparation of Internal Standard and Calibrators. Bupro-
pion, hydroxybupropion (calibrators), internal stan-
dard 1 (bupropion-d9), and internal standard 2
(hydroxybupropion-d6) were extracted from 100 μL
of human plasma by protein precipitation. The in-
ternal standards were prepared by diluting 50 μL of
bupropion-d9 stock + 200 μL hydroxybupropion-d6
stock with 20 mL acetonitrile + 20 mL deionized
water to yield a final concentration of 125 ng/mL
bupropion and 500 ng/mL hydroxybupropion. For
calibration, a substock solution containing bupropion
and hydroxybupropion was prepared by diluting 50 μL
of bupropion stock (1 mg/mL) and 200 μL hydrox-
ybupropion stock (1 mg/mL) in 20 mL of human
plasma.
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Table 1. Subject Demographics
Bupropion Subjects (N = 24) Montelukast Subjects (N = 24)
Age (y) Mean (SD) range 32.6 (7.14) 20-45 30.8 (7.1) 20-43
Race n (%) White 18 (75.0) 19 (79.2)
Black 3 (12.5) 4 (16.7)
Asian 1 (4.2) 0
Mixed race 2 (8.4) 1 (4.2)
Ethnicity n (%) Not Hispanic or Latino 23 (95.8) 24 (100.0)
Hispanic or Latino 1 (4.2) 0
Mean (SD) 178.7 (5.32) 180.2 (8.1)
Height (cm) Range 169-188 164-199
Mean (SD) 78.07 (9.46) 81.22 (12.24)
Weight (kg) Range 64.3-99.8 61.9-104.9
Mean (SD) 24.46 (2.80) 25.00 (3.38)
BMI (kg/m2) Range 20.0-30.1 19.4-30.0
History of smoking n (%) 4 (16.7) 4 (16.7)
Consumes any alcohol (%) 15 (62.5) 17 (70.8)
Units/week mean (SD) 5.8 (3.8) 5.7 (4.2)
Alcohol consumption Rangea 1-12 1-17
BMI indicates body mass index.
aIncludes only those subjects who drink alcohol.
Days 1–5 Days 6–15 Days 16–21 Day22 Days 23–28
Day
29
A A A A A A A A A A
B B B B
Figure 1. Bupropion dosing intervals. A, dosing with amenamevir 400 mg once daily; B, dosing with bupropion 150 mg.
Table 2. Bupropion and Hydroxybupropion Variability
Concentration Mean Precision Accuracy
(ng/mL) (ng/mL) (%CV) (%)
Bupropion
QC1 5 4.640 5.1 92.9
QC2 75 69.86 4.2 93.2
QC3 200 192.5 3.6 96.3
Hydroxybupropion
QC1 20 19.24 7.5 96.2
QC2 300 286.1 5.0 95.4
QC3 800 781.1 4.9 97.3
QC indicates quality control.
Analytical Method. We then added to a 2-mL
polypropylene tube 100 μL of calibrator or plasma
sample, 50 μL of internal standard (125 ng/mL
bupropion-d9 and 500 ng/mL hydroxybupropion-d6),
200 μL precipitating agent (acetonitrile), and 200 μL
of deionized water.
The sample was vortexed for 2 minutes before cen-
trifugation and 150 μL supernatant was transferred to
an autosampler tube and submitted to analysis by liq-
uid chromatography tandem mass spectrometry.
HPLC Conditions. The analytic column was an Onyx
Monolithic C18 column (100 mm × 3 mm) (Phe-
nomenex, Torrance, California). The mobile phase
comprised methanol 1000 mL, deionized water 1000
mL, plus 10 g ammonium formate. Elution was iso-
cratic at a flow rate of 300 μL/min.
MS Settings. An Applied Biosystems (Foster City,
California) API4000 mass spectrometer was used with
turbo ion spray and positive ionization. Mass ratios
were 240.0/184.0 amu for bupropion, 249.0/185.0 amu
for the bupropion standard, 256.0/167.0 amu for hy-
droxybupropion, and 282.0/130.0 amu for the hydroxy-
bupropion standard.
Variability. Variabilities of bupropion and hydroxy-
bupropion determinations are shown in Table 2.
Montelukast
Preparation of Internal Standard and Calibrators. Mon-
telukast, montelukast 1,2-diol (calibrators), and
montelukast-d6 (internal standard) were extracted from
100 μL of human plasma by protein precipitation.
Working solutions at a concentration of 1000 ng/mL
were prepared by diluting an aliquot (25 μL) of stock
solution (1000 μg/mL) with analyte-free plasma up to
a final volume of 25 mL.
Analytical Method. We added to a 2-mL polypropy-
lene tube 100μL of calibrator or plasma sample, 25μL
of internal standard (montelukast-d6), and 500 μL of
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Table 3. Montelukast and Montelukast 1,2-diol variability
Concentration Mean Precision Accuracy
(ng/mL) (ng/mL) (%CV) (%)
Montelukast
QC1 20.1 20.14 8.7 100.2
QC2 150.4 149.6 7.0 99.5
QC3 752.2 727.7 7.889 96.747
Montelukast 1,2-diol
QC1 2.0 1.951 13.3 97.6
QC2 14.7 13.70 13.4 93.2
QC3 73.5 70.80 15.0 96.3
QC indicates quality control.
precipitating solution (acetonitrile:methanol, 1:1). The
sample was vortexed for 2 minutes before centrifuga-
tion. The supernatant was transferred into a polypropy-
lene autosampler tube, and 10 μL was injected onto
the high-precision liquid chromatography tandemmass
spectrometer. Because the drug,metabolite and internal
standard are all light sensitive, steps were taken to min-
imize exposure to light throughout.
HPLC Conditions. The column used was a Mono-
lith PR-18e column (100 mm × 3.0 mm). The mobile
phase comprised 1000 mL acetonitrile, 1000 mL deion-
ized water, and ammonium formate 5 g. Elution was
isocratic at a flow rate of 300 μL/min.
MS Settings. An Applied Biosystems API4000 mass
spectrometer was used with turbo ion spray and pos-
itive ionization. Mass ratios were 586.4/422.1 amu for
montelukast, 592.3/427.1 amu for the motelukast stan-
dard, 602.4/438.0 amu formontelukast 1,2-diol, and for
hydroxybupropion, and 592.3/427.1 amu for the mon-
telukast 1,2-diol standard.
Variability. Variabilities of montelukast and mon-
telukast 1,2-diol are shown in Table 3.
Sample Size
A sample size of 24 subjects for the montelukast study
was selected based on a statistical power calculation.
From published studies, estimates of between-subject
percentage coefficient of variation (%CV) for Cmax and
AUC0- were 20% to 30%.7 Statistical power was es-
timated by 10,000 simulations using the model below.
The model included treatment (montelukast in combi-
nation with amenamevir and montelukast alone), se-
quence, and session as fixed effects and subject as a
random effect.
ln
(
PKparameterijkl
) = Treatmenti + Sessionj
+ Sequencek + Subjectl + eijkl
Given a %CV of 25, a true mean ratio of 1.0, and an
acceptance limit of 80% to 125% for 90%CI, a sample
size of 24 subjects would provide at least 86% power to
detect an interaction, as defined by the criteria above. In
practice, within-subject variability was likely to be less
than between-subject variability.
A sample size of 24 subjects was selected for the
bupropion study based on a statistical power calcula-
tion. Two previous studies of single doses of 150 mg
bupropion gave within-subject estimates of %CV for
Cmax and AUC0– between 15% and 30%.20,21 Statis-
tical power was estimated by simulation (the number
of simulations was 10,000) using the model below. The
model included treatment (bupropion in combination
with amenamevir and bupropion alone) as a fixed ef-
fect and subject as a random effect.
ln (PKparameter)ij = Treatmenti + Subjectj + εij
Given a %CV of 22.5 (the average of 15% and 30%),
a true mean ratio of 1.0, and an acceptance limit of
80% to 125% for the 90%CI, a sample size of 24 sub-
jects would provide 93% power.
Pharmacokinetic and Statistical Analysis
Pharmacokinetic parameters were calculated using
WinNonlin (Certara, Princeton, New Jersey) ver-
sion 6.3. Interactions were tested using an equivalence
analysis.
To assess the effect of amenamevir on montelukast,
montelukast in combination with amenamevir was
compared with montelukast alone. The AUC0- and
Cmax were logarithmically transformed and subjected
to ANOVAwith treatment (montelukast alone or mon-
telukast in combination with amenamevir), sequence,
and session as fixed effects and subject as a random ef-
fect. Absence of a clinically significant effect of ame-
namevir on the pharmacokinetics of montelukast was
concluded if the 90%CI for both AUC0- and Cmax
ratios fell within the prespecified interval of 80% to
125%. To assess the effect of amenamevir on methyl-
hydroxymontelukast, montelukast in combination with
amenamevir was compared with montelukast alone us-
ing the method described above.
To assess the effect of amenamevir on CYP2B6
activity, bupropion in combination with amenamevir
(Test) was compared with bupropion alone on day 1
(Reference). Briefly,AUC0– andCmax were logarithmi-
cally transformed and subjected to ANOVA with treat-
ment (bupropion alone or bupropion in combination
with amenamevir) as a fixed effect and subject as a ran-
dom effect. The least-squares mean of the treatment
difference and its 90%CI, were transformed to the orig-
inal scale in order to obtain themeanAUC0- and Cmax
ratios (bupropion in combination with amenamevir rel-
ative to bupropion alone). Absence of a clinically sig-
nificant drug-drug effect of amenamevir on bupropion
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Figure 2. Mean montelukast plasma concentration-time plots (linear and semilogarithmic, N = 24). Values below the limit of quan-
tification were entered as 0 and included in the calculation of means.
Figure 3. Mean methyl-hydroxymontelukast plasma concentration-time plots (linear and semilogarithmic,N = 24). Values below the
limit of quantification were entered as 0 and included in the calculation of means.
was concluded if the 90%CI for both AUC0– and
Cmax ratios fell within the prespecified interval of
80% to 125%. To assess the effect of amenamevir
on hydroxybupropion, bupropion in combination with
amenamevir (Test) was comparedwith bupropion alone
(Reference) using the method described above.
To assess the recovery of CYP2B6 activity, the effect
of amenamevir on bupropion was assessed on days 22
and 29 using the method described above. The 95%CIs
for the difference in means (day 22 vs day 1 and day 29
vs day 1) were used to determine how long it took for
CYP2B6 activity to return to normal.
Results
Montelukast Study
Mean age, weight, and body mass index were sim-
ilar across treatment sequences. There were no no-
table differences in race, ethnicity, or the subjects’ usual
cigarette smoking or alcohol intake habits.
From about 1 hour after dosing until 30 hours post-
dose, mean plasma concentrations of montelukast were
about 1.2-fold higher when montelukast was coad-
ministered with amenamevir than when given alone
(Figure 2, Supplementary Table S1). After both treat-
ments, mean montelukast plasma concentrations ap-
proached LLQ at 24 hours after dosing, and were below
the limit of quantification by 30–36 hours after dosing.
At all time points from 1 to 30 hours after
dosing, mean plasma concentrations of methyl-
hydroxymontelukast were 1.2- to 2.2-fold higher when
montelukast was taken with amenamevir than when
given alone (Figure 3, Supplementary Table S2).
Both after montelukast alone and combined
with amenamevir, mean methyl-hydroxymontelukast
plasma concentration approached LLQ at 20 hours
after dosing, and was below the limit of quantification
by 36–48 hours after dosing.
Both Cmax and AUC0- of montelukast increased
significantly, by about 22% (Tables 4 and 5), when com-
bined with amenamevir (121.7%, 90%CI [114.8, 129.1];
122.1% [116.2, 128.4] respectively), as did Cmax and
AUC0- of its primary metabolite hydroxymontelukast
(121.4%, 90%CI [106.4, 138.5]; 125.6 % [111.3, 141.7]).
After coadministration of amenamevir, the time to
peak montelukast concentration remained unchanged.
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Table 4. Summary of Effects of Amenamevir on Cmax and AUC0- of Montelukast and Methyl-Hydroxymontelukast Using Log-
Transformed Values (N = 24)
Least-Squares Means
Montelukast With Amenamevir
vs Montelukast Alone
Analyte Parameter
Montelukast With
Amenamevir Montelukast Ratio (%) 90%CI
Montelukast Cmax (ng/mL) 505.9 415.6 121.7 114.8, 129.1
AUC0- (h·ng/mL) 3418.5 2799.2 122.1 116.2, 128.4
Methyl-hydroxymontelukast Cmax (ng/mL) 23.3 19.2 121.4 106.4, 138.5
AUC0- (h·ng/mL) 188.6 150.2 125.6 111. 3, 141.7
AUC0- indicates area under concentration-time curve extrapolated to infinite time; Cmax, peak concentration.
Table 5. Summary of Montelukast Pharmacokinetic Parameters
Parameter
Montelukast
Alone
(N = 24)
Montelukast
With
Amenamevir
(N = 24)
Cmax (ng/mL) Mean 427.5 521.5
SD 103.2 131.5
AUC0-tn (h·ng/mL) Mean 2820.6 3460.2
SD 869.6 1114.0
AUC0- (h·ng/mL) Mean 2916.3 3567.5
SD 878.9 1115.7
Tmax (h) Median 3.00 3.00
Range 2.00-6.00 1.50-5.00
t½ (h) Mean 5.05 5.45
SD 1.40 0.92
CL/F (L/h) Mean 3.72 3.04
SD 1.08 0.86
AUC0- indicates area under concentration-time curve extrapolated to
infinite time; AUC0-tn, area under concentration-time curve up to last
nonzero value; CL/F, apparent total body clearance from plasma; Cmax,
peak concentration; t½, half-life; Tmax, time of peak concentration.
The elimination half-life of montelukast was slightly
increased, and apparent total body clearance was
slightly reduced after coadministration of amenamevir
(neither was statistically significant).
Overall, 7 subjects (29.2%) reported 9 adverse events
(AEs): each of those subjects reported an AE after
10 mg montelukast alone, and 2 subjects (8.3%) also
reported an AE after 10 mg montelukast with 400 mg
amenamevir. Most AEs occurred at least 72 hours after
dosing, and only 1 subject required concomitant med-
ication within 72 hours after dosing (paracetamol for
pharyngitis).
All AEs were of mild or moderate intensity. Mod-
erate AEs were more frequent after 10 mg montelukast
alone (16.7% of subjects) than after 10 mgmontelukast
with 400 mg amenamevir (4.2% of subjects). Mild AEs
were reported by more subjects (12.5%) after 10 mg
montelukast alone than after 10 mg montelukast with
400 mg amenamevir (4.2% of subjects).
Bupropion Study
From about 2 to 6 hours after dosing, mean plasma
concentrations of bupropion were lower when bupro-
pion was taken with amenamevir than when it was
taken alone, whether on day 1 (before amenamevir had
been given), or on days 22 and 29 (a week or more af-
ter repeated amenamevir dosing had ended (Figure 4,
Supplementary Table S3).
After all treatments, mean bupropion plasma con-
centrations were approaching the LLQ at 36 hours after
dosing and were below LLQ by 96 hours after dosing.
Plasma concentrations of bupropion after a single
150-mg dose were about 16% lower after 10 days’ dos-
ing with amenamevir than when it was given alone, as
evidenced by the reduction in both Cmax and AUC0–
to about 84% (84.29%, 90%CI [78.00, 91.10]; 84.07%,
90%CI [78.85, 89.63], respectively) (Table 6). Plasma
concentrations then recovered to pretreatment levels on
days 22 and 29.
Bupropion concentrations on day 22 were similar to
those on day 1 (ratio 104.07, 95%CI [94.74, 114.32]),
indicating that the induction of CYP2B6 by repeated
doses of amenamevir had remitted by 1 week after the
last dose of amenamevir (Table 7).
Figure 5 shows the mean plasma concentrations of
hydroxybupropion plotted against time. On day 1, the
AUC of the primary metabolite hydroxybupropion was
about 15-fold that of the parent molecule (Table 8).
Coadministration of amenamevir with bupropion
had no significant effect on plasma concentrations of
hydroxybupropion.
Median time to peak concentration of bupropion
was 3 hours on days 1, 15, 22, and 29 (Table 9). Mean
t½ was shortened by amenamevir on day 15 by around
2 hours compared with that on day 1; consistent with
that finding and with the reduction in AUC of bupro-
pion, apparent total body clearance of bupropion was
slightly higher when given with amenamevir than when
given alone.
Overall, 12 subjects (50.0%) reported AE. Headache
was the most frequently reported AE. Cannula site
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Figure 4. Mean bupropion plasma concentration-time plots (linear and semilogarithmic, N = 24). Values below the limit of quantifi-
cation were entered as 0 and included in the calculation of means.
Table 6. Summary of the Effect of 10 Days’ Pretreatment With Amenamevir on Cmax and AUC0- on a Single Dose of Bupropion
(Day 15, N = 24) with 90%CIs
Least-Squares Means
Bupropion With Amenamevir vs
Bupropion Alone
Bupropion
Parameter
Bupropion With
Amenamevir Bupropion Ratio (%) 90%CI
Cmax (ng/mL) 76.94 91.28 84.29 78.00, 91.10
AUC0-
(h·ng/mL)
653.70 777.61 84.07 78.85, 89.63
AUC0– indicates area under concentration-time curve extrapolated to infinite time; Cmax, peak concentration.
Parameters have been log-transformed.
Table 7. Summary of Bupropion Concentrations Before, During, and After Induction of CYP2B6 by Amenamevir (N = 24) With
95%CIs
Parameter Day 1 (Control) Day 15 Day 22 Day 29
Cmax LS mean 91.28 76.94 92.21 95.00
(ng/mL) ratio vs control (%) (95%CI) N/A 84.29 (76.74, 92.60) 101.02 (91.96, 110.97) 104.07 (94.74, 114.32)
AUC0- LS mean 777.61 653.70 785.52 841.36
(h·ng/mL) ratio vs control (%) (95%CI) N/A 84.07 (78.12, 90.46) 101.02(93.88, 108.70) 108.20 (100.55, 116.43)
AUC0– indicates area under concentration-time curve extrapolated to infinite time; Cmax, peak concentration; LS mean, least-squares mean; N/A,
not applicable. Parameters have been log-transformed.
Figure 5. Hydroxybupropion plasma concentration-time plots (linear and semilogarithmic, N = 24). Values below the limit of quan-
tification were entered as 0 and included in the results.
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Table 8. Summary of Hydroxybupropion Pharmacokinetic Parameters
Bupropion Parameter
Day 1
Bupropion
Alone (N = 24)
Day 15 Bupropion +
Amenamevir (N = 24)
Day 22
Bupropion
Alone (N = 24)
Day 29
Bupropion
Alone (N = 24)
Cmax (ng/mL) Mean 308.0 315.1 310.8 304.2
SD 87.8 96.8 79.5 86.5
AUC0-tn (h·ng/mL) Mean 11,045.1 10,807.2 11,725.4 11,623.6
SD 3471.9 3828.3 3814.3 3858.9
AUC0- (h·ng/mL) Mean 11,784.3 11,556.5 12,754.5 12,559.6
SD 3882.3 4263.4 4423.4 4238.0
Tmax (h) Median 8.00 8.00 8.00 8.00
Range 4.00-10.08 5.00-24.00 5.00-12.00 3.00-12.02
t½ (h) Mean 21.83 21.42 23.70 23.19
SD 4.70 4.94 5.76 3.74
AUC0- indicates area under concentration-time curve extrapolated to infinite time;AUC0-tn, area under concentration-time curve up to last nonzero
value; Cmax, peak concentration; t½, half-life; tmax, time of peak concentration.
Table 9. Summary of Bupropion Pharmacokinetic Parameters
Bupropion Parameter
Day 1
Bupropion
Alone (N = 24)
Day 15 Bupropion +
Amenamevir (N = 24)
Day 22
Bupropion
Alone (N = 24)
Day 29
Bupropion
Alone (N = 24)
Cmax (ng/mL) Mean 94.5 80.3 95.6 97.8
SD 25.8 24.4 26.9 24.5
AUC0-tn (h·ng/mL) Mean 764.5 629.8 777.5 825.7
SD 246.9 175.5 242.5 235.7
AUC0- (h·ng/mL) Mean 812.6 675.7 820.9 873.7
SD 269.0 188.7 253.1 245.5
Tmax (h) Median 3.00 3.00 3.00 3.00
Range 2.00-6.00 1.00-5.98 2.00-5.00 1.00-5.00
t½ (h) Mean 10.92 8.97 9.76 11.87
SD 6.09 5.08 4.01 5.24
CL/F (L/h) Mean 200.64 236.46 199.59 185.59
SD 56.33 57.20 62.04 57.71
AUC0– indicates area under the concentration-time curve extrapolated to infinite time; AUC0-tn, area under concentration-time curve up to last
nonzero value; CL/F, apparent total body clearance from plasma; Cmax, peak concentration; t½, half-life; tmax, time of peak concentration.
pain, rhinitis, back pain, and anxiety were reported by 2
subjects each. No other AE was reported by more than
1 subject.
Discussion
Montelukast
Coadministration of amenamevir with montelukast
caused a 22% increase in both Cmax and AUC of
montelukast. The data failed to exclude a clinically
significant drug-drug effect because the 90%CI of the
log ratio montelukast versus amenamevir plus mon-
telukast did not fall within the range 80% to 125% for
both Cmax and AUC. The increase in Cmax is consistent
with a reduction in first-pass intestinal and hepatic
extraction. Apparent clearance and t½ showed a trend
toward reduction in rate of elimination of montelukast.
Our results are consistent with the in vitro finding that
amenamevir is a weak inhibitor of CYP2C8. An
increase of 22% in plasma concentration of a drug that
is a substrate of CYP2C8 would be of importance only
for medicines with a very narrow therapeutic window,
so reduction of the dose of concurrent medication is
unlikely to be necessary in clinical practice.
Coadministration of amenamevir with montelukast
was associated with a mean 22% increase in plasma
Cmax and AUC of montelukast’s major metabolite,
methyl-hydroxymontelukast. That increase mirrored
the 22% increase in Cmax and AUC of parent mon-
telukast and is likely due to the metabolite also being
dependent on CYP2C8 for subsequent conversion.
Thus, rather than concentration decreasing as might
be expected, it increased in parallel due to inhibition
in a manner consistent with the effect on the parent
compound.
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Montelukast is metabolized not only by CYP2C8
but also by CYP3A4, of which amenamevir is both a
substrate and inducer. However, CYP2C8 is believed to
account for about 80% of montelukast’s metabolism:
inhibition of CYP2C8 by gemfibrozil increases the
AUC of montelukast 4-fold.9 The same study also
showed that inhibition of CYP3A4 by itraconazole did
not affect the metabolism of montelukast, in contrast
with later findings7,9: in 1 study, inhibition of CYP3A4
increased AUC of montelukast by 144%.7 Thus,
current evidence is contradictory, but it is certainly
conceivable that induction of CYP3A4 activity by
amenamevir might reduce plasma concentrations of
montelukast. However, amenamevir was given only as
a single dose together with a single dose of montelukast
in this study, and it is unlikely that CYP3A4 induction
by amenamevir could have developed quickly enough
to have influenced the results.
In respect to safety and tolerability, both single and
combined dosing were equally well tolerated in the
healthy men in this study.
Bupropion
Amenamevir 400 mg once daily for 10 days decreased
both Cmax and AUC0- of bupropion by about 16%.
The results did not exclude a significant effect of ame-
namevir on bupropion exposure, as the 90%CI of the
least-squares geometric mean ratios (bupropion with
amenamevir to bupropion) of Cmax and AUC0- did
not fall within the prespecified interval of 80% to 125%.
At 1 and 2 weeks (days 22 and 29) after the final dose
of amenamevir, Cmax, and AUC0- of bupropion were
similar to those on day 1, indicating that CYP2B6 activ-
ity had returned to pretreatment levels within 1 week af-
ter the last amenamevir dose. That is consistent with the
observation that even extensive induction of CYP2B6
by rifampicin is fully reversed by 2 weeks after cessa-
tion of rifampicin treatment.22
Prior treatment with amenamevir 400 mg once daily
for 10 days did not affect Cmax or AUC0- of hydroxy-
bupropion, which is bupropion’s main metabolite. Be-
cause amenamevir treatment did reduce AUC0- of
bupropion parent drug, there was a small change in
the ratio of AUC0- for hydroxybupropion:bupropion;
before amenamevir the ratio was 15.2; after treatment
with amenamevir, the corresponding ratio was 17.7.
Those results are consistent with the findings of Laizure
et al, who showed that the more powerful induction of
CYP2B6 by rifampicin reduced AUC0- of bupropion
by 3-fold, but doubled AUC0- of the hydroxybupro-
pion metabolite.15
The minor reduction (by 16%) in plasma concen-
trations of bupropion, coupled with no change in
concentrations of the active metabolite hydroxybupro-
pion, would be unlikely to warrant dose adjustment
when amenamevir is coadministeredwithCYP2B6 sub-
strates.
Our AE data showed that repeated doses of 400 mg
amenamevir, given alone orwith a single dose of 150mg
bupropion, were well tolerated in healthy men.
Conclusions
Theminor increase (22%) of the concentration of mon-
telukast and the similarly marginal reduction (16%)
in plasma concentration of bupropion suggest that
dose adjustment is unlikely to be necessary when ame-
namevir is coadministered with CYP2C8 or CYP2B6
substrates.
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